The European Commission has approved Kisunla, a treatment for mild cognitive impairments, including dementia in the early stages of Alzheimer's disease. Although the drug, based on the molecule donanemab, has shown promising results in clinical trials, controversy remains regarding its actual benefits and the risks of serious side effects. The authorization is conditional on its administration only to patients without genetic mutations that could increase the risks. EU member states have the freedom to decide on reimbursement, and other countries, such as the United Kingdom, have adopted a similar approach.
Sources
Uniunea Europeană autorizează Kisunla, un tratament al Eli Lilly controversat împotriva maladiei Alzheimer. În afară de beneficii reale modeste, are efecte secundare grave, uneori mortale, şi anume hemoragii şi edeme cerebrale
UE a aprobat un nou medicament pentru Alzheimer
UE a aprobat un nou tratament controversat împotriva Alzheimer
Noi tratamente împotriva Alzheimer: UE a autorizat un medicament promițător, dar cu efecte secundare grave posibile
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
O nouă speranță pentru pacienții cu ALZHEIMER. Comisia Europeană aprobă primul tratament care poate încetini evoluția bolii
Comisia Europeană a autorizat comercializarea unui medicament pentru tratarea bolii Alzheimer în stadii incipiente
Latest News
23:03
Kallas says Usmanov and Fridman will not return to the EU list anytime soon, while sanctions on more than 3,000 individuals and entities are extended until 2029
22:56
Cristian Tudor Popescu: Luca Niculescu cannot form a government under the current political configuration
22:50
Iranian President Masoud Pezeshkian rejects negotiations with the US: “They make no sense”
22:49
Vladimir Putin approves the reorganization and sale of UniCredit’s Russian subsidiary
22:41
Moldova is gradually extending VAT and excise duties to goods brought in by operators from Transnistria as part of its economic reintegration strategy
See more news